The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Shrestha, Sadeep ^a   Sudenga, Staci L ^a   Smith, Jennifer S ^b   Bachmann, Laura H ^c,d   Wilson, Craig M ^a   Kempf, Mirjam C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b IL   (United States)

^c WG Hefner Medical Center   (United States)

^d WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PERSISTENT VIRUS INFECTION; PREVALENCE; TREATMENT OUTCOME; VAGINAL LAVAGE; VIRUS TYPING; WART VIRUS; CHILD; CLASSIFICATION; GENETICS; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVIX UTERI; CHILD; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; YOUNG ADULT;

EID: 77957791268     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-295     Document Type: Article

References (42)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(11):796-802. 10.1093/jnci/87.11.796, 7791229.
2. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006, 61(6 Suppl 1):S3-14. 10.1097/01.ogx.0000221010.82943.8c, 16729902.
3. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. Jama 2007, 297(8):813-819. 10.1001/jama.297.8.813, 17327523.
4. Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004, 36(1):6-10. 10.1363/3600604, 14982671.
5. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000, 151(12):1158-1171.
6. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004, 36(1):11-19. 10.1363/3601104, 14982672.
7. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338(7):423-428. 10.1056/NEJM199802123380703, 9459645.
8. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998, 132(2):277-284. 10.1016/S0022-3476(98)70445-7, 9506641.
9. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100(7):513-517. 10.1093/jnci/djn044, 18364507.
10. Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, Brown W, Frost A, Tabara SO, Shah K. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis 1998, 25(5):243-250. 10.1097/00007435-199805000-00005, 9587175.
11. Koshiol J, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006, 164(2):176-183. 10.1093/aje/kwj165, 16775041.
12. Lehtinen M, Luukkaala T, Wallin KL, Paavonen J, Thoresen S, Dillner J, Hakama M. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 2001, 22(1):117-124. 10.1016/S1386-6532(01)00172-X, 11418359.
13. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000, 151(12):1148-1157.
14. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997, 337(19):1343-1349. 10.1056/NEJM199711063371903, 9358128.
15. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman P, et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006, 119(7):1623-1629. 10.1002/ijc.22015, 16646070.
16. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004, 190(1):37-45. 10.1086/421467, 15195241.
17. Minkoff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 1998, 178(5):982-986. 10.1016/S0002-9378(98)70535-6, 9609571.
18. Ahdieh L, Klein RS, Burk R, Cu-Uvin S, Schuman P, Duerr A, Safaeian M, Astemborski J, Daniel R, Shah K. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001, 184(6):682-690. 10.1086/323081, 11517428.
19. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007, 99(12):962-972. 10.1093/jnci/djm010, 17565153.
20. Bratcher LF, Sahasrabuddhe VV. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer 5:8. 10.1186/1750-9378-5-8, 2881893, 20462441.
21. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. Aids 1998, 12(12):1459-1464. 10.1097/00002030-199812000-00007, 9727566.
22. Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. Aids 2002, 16(13):1799-1802. 10.1097/00002030-200209060-00013, 12218392.
23. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, Muderspach L, Burk R, Palefsky J. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. Aids 2001, 15(16):2157-2164. 10.1097/00002030-200111090-00011, 11684935.
24. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, Moxley M, Palefsky J, Sacks H, Burk RD, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004, 96(14):1070-1076. 10.1093/jnci/djh192, 15265968.
25. Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001, 184(4):538-543. 10.1067/mob.2001.111103, 11262450.
26. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, Lodini S, Mastrorilli E, Taccagni G, Lazzarin A, Uberti-Foppa C. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001, 184(5):547-551. 10.1086/322856, 11494160.
27. Del Mistro A, Bertorelle R, Franzetti M, Cattelan A, Torrisi A, Giordani MT, Sposetti R, Bonoldi E, Sasset L, Bonaldi L, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004, 38(5):737-742. 10.1086/381681, 14986260.
28. Uberti-Foppa C, Ferrari D, Lodini S, Reina S, Ameglio F, Grasso MA, Gallotta G, Ferrari A, Taccagni G, Lazzarin A, et al. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. Aids 2003, 17(14):2136-2138. 10.1097/00002030-200309260-00021, 14502023.
29. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, Rompalo AM, Cu-Uvin S, Duerr A. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009, 113(1):26-31.
30. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008, 17(6):545-554. 10.1097/CEJ.0b013e3282f75ea1, 18941376.
31. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB. The REACH (Reaching for Excellence in Adolescent Care and Health) project: study design, methods, and population profile. J Adolesc Health 2001, 29(3 Suppl):8-18. 10.1016/S1054-139X(01)00291-9, 11530299.
32. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. Aids 2002, 16(17):2275-2284. 10.1097/00002030-200211220-00007, 12441799.
33. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 1998, 22(4):300-311. 10.1016/S1054-139X(97)00279-6, 9561462.
34. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV. Annals of Internal Medicine 2002, 137(5):381-433.
35. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 2001, 13(1):27-40. 10.1080/09540120020018161, 11177463.
36. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, Levin L, Wilson CM. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med 2000, 154(2):127-134.
37. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007, 90:1-636.
38. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009, 10(4):321-322. 10.1016/S1470-2045(09)70096-8, 19350698.
39. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006, 107(1):18-27.
40. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255. 10.1016/S0140-6736(06)68439-0, 16631880.
41. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366(9490):991-998. 10.1016/S0140-6736(05)67069-9, 16168781.
42. Vermund SH, Wilson CM, Rogers AS, Partlow C, Moscicki AB. Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH study. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health 2001, 29(3 Suppl):49-56. 10.1016/S1054-139X(01)00296-8, 11530303.